TROVAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TROVAN (TROVAN).
Trovan (trovafloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
| Metabolism | Trovafloxacin is primarily metabolized by the liver via glucuronidation and oxidation, with involvement of cytochrome P450 enzymes (minor contribution). It has a long half-life (~10-12 hours). |
| Excretion | Renal (approximately 60% unchanged) and fecal/biliary (approximately 35% as unchanged drug and metabolites). |
| Half-life | Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function, supporting twice-daily dosing. |
| Protein binding | Approximately 88% bound to serum proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 1.3 L/kg, indicating extensive tissue penetration, including into lung, sinus, and prostate tissues. |
| Bioavailability | Oral bioavailability is approximately 88% (tablets) and 95% (oral suspension). |
| Onset of Action | Oral: ~1-2 hours; Intravenous: immediate (within minutes). |
| Duration of Action | 12 hours (consistent with dosing interval); clinical effects persist for at least 24 hours due to post-antibiotic effect. |
| Molecular Weight | 416.26 |
200 mg IV once daily for 7-14 days for community-acquired pneumonia; 200 mg orally once daily for 7-14 days for acute exacerbation of chronic bronchitis
| Dosage form | TABLET |
| Renal impairment | No adjustment necessary for mild to moderate renal impairment; not recommended for patients with creatinine clearance <40 mL/min |
| Liver impairment | Contraindicated in patients with Child-Pugh class C; use with caution in class A and B, no specific dose adjustment defined |
| Pediatric use | Not recommended for pediatric patients due to risk of arthropathy; no established dosing |
| Geriatric use | No specific dose adjustment required; monitor renal function as elderly may have decreased clearance |
| 1st trimester | Avoid during first trimester; animal studies show embryotoxicity and teratogenicity (e.g., skeletal malformations). No adequate human studies; potential risk to fetus outweighs benefits. |
| 2nd trimester | Avoid during second trimester; fluoroquinolones are associated with arthropathy in juvenile animals and theoretical risk to fetal cartilage development. |
| 3rd trimester | Avoid during third trimester; risk of fetal cartilage damage and possible CNS effects. Use only if benefit justifies risk to fetus. |
Clinical note
Comprehensive clinical and safety monograph for TROVAN (TROVAN).
| Placental transfer | Trovafloxacin crosses the placenta to some extent. Animal studies indicate distribution to fetal tissues, including bone and muscle, with binding to cartilage. |
| Breastfeeding | Trovan (trovafloxacin) is excreted into breast milk in low concentrations. However, due to potential adverse effects on nursing infant (e.g., gastrointestinal disturbances, CNS effects, and arthropathy), caution is advised. The manufacturer recommends discontinuing breastfeeding or the drug, considering the importance of the drug to the mother. |
■ FDA Black Box Warning
Trovan is associated with an increased risk of hepatotoxicity, including acute liver failure and death. Its use should be reserved for patients with serious infections who are hospitalized and for whom alternative treatments are not available or appropriate.
| Serious Effects |
History of hypersensitivity to trovafloxacin, alatrofloxacin, or any fluoroquinoloneKnown prolongation of QT interval or concurrent use of Class IA/III antiarrhythmicsUncorrected electrolyte disorders (e.g., hypokalemia, hypomagnesemia)Bradycardia or significant cardiac diseaseConcurrent use of other drugs that prolong QT intervalHepatic failure or prior liver injury associated with trovafloxacin useMyasthenia gravis (absolute contraindication due to neuromuscular blockade)
| Precautions | Hepatotoxicity (discontinue at first signs of hepatic injury); QT prolongation; tendon damage (increased risk in patients over 60, those on corticosteroids, and organ transplant recipients); peripheral neuropathy; CNS effects (seizures, dizziness); photosensitivity; Clostridium difficile-associated diarrhea; myasthenia gravis exacerbation. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | TROVAN (trovafloxacin) is contraindicated in pregnant women. In animal studies, trovafloxacin caused fetal toxicity (increased fetal loss, reduced fetal weight) and skeletal abnormalities at clinically relevant doses. Human data are insufficient, but fluoroquinolones as a class are associated with arthropathy in juvenile animals and potential cartilage damage in humans. Risk cannot be excluded; avoid use in all trimesters. |
| Fetal Monitoring | Monitor for signs of fetal distress if inadvertent exposure occurs. No specific monitoring required as drug is contraindicated. If used inadvertently, consider fetal ultrasound for skeletal development. |
| Fertility Effects | No human data on fertility effects. Animal studies show no impairment of fertility at therapeutic doses. However, fluoroquinolones may adversely affect spermatogenesis in some animal models; clinical significance unknown. |
| Avoid dairy products (milk, yogurt) and calcium-fortified foods within 4 hours of taking Trovan, as they reduce absorption. No other significant food interactions. |
| Clinical Pearls | Trovan (trovafloxacin) is associated with rare but severe hepatotoxicity, leading to its restricted use. Monitor liver function tests before and during therapy. Avoid use in patients with liver disease. Due to risk of CNS effects, caution in patients with seizure disorders. Avoid concomitant use with NSAIDs due to increased CNS stimulation risk. |
| Patient Advice | Trovan can cause severe liver injury; report symptoms like jaundice, dark urine, or abdominal pain immediately. · Avoid alcohol while taking Trovan. · May cause dizziness or lightheadedness; avoid driving until you know how you react. · Take exactly as prescribed; do not stop early as some infections require full course. · Do not take with antacids, iron, or zinc supplements; take 4 hours apart. |